The global malaria vaccines market size was valued at USD 12.3 million in 2018 and is expected to grow at a CAGR of around 33.2% from 2019 to 2026. Malaria is a widespread disease that is caused by a parasitic infection by the protozoan plasmodium usually transmitted by different species of anopheles mosquitoes. Amongst the different plasmodium varieties, 4 of them uses people as an all-natural intermediate host. These are P. ovale, P. vivax, P. falciparum, as well as P. malaria. A report by WHO estimates that there were more than 219 million cases of malaria in more than 90 countries across the globe. In 2017 however, P. falciparum represented 99.7% of approximated malaria situations in the African region, in addition to most of instances in the regions of of South-East Asia (62.8%), the Eastern Mediterranean (69%) and also the Western Pacific (71.9%). P.vivax represented 74.1% or malaria cases in the Americas, majorly dominating the Latin American region. It is observed that greater than 85% of fatality by malaria is triggered because of P. falciparum and afterwards practically 90% of fatalities of malaria are triggered in Sub-Saharan Africa by P. falciparum.
These expanding occurrences of malaria in addition to the existence of various pharmaceutical companies that are introducing low profit margin malaria vaccines are anticipated to enhance the market for malaria vaccines. Globally the need for these vaccines is most likely to be more driven by the growing awareness pertaining to the aftereffects of the disease. It is anticipated that in the coming years, the market might deal with difficulties related to the high prices of the vaccines, weak supply chain or distribution network in the developing nations, along with rigid regulative plans, acting as some primary restrictions for the market development. Furthermore, it is anticipated that the continuous R&D activities carried out by different pharma companies, inoculation programs, technical innovations as well as financial investments will likely offer new growth opportunities in this market in future.
Know more about this report: request for sample pages
Based on the data provided by World Health Organization, it is estimated that more than 92% of malaria cases and 93% of deaths in the African region were due to malaria, thus making this region as more prone to this disease and one of the largest potential regions that needs malaria vaccines. In addition to this, it is the limited financial resources, lower awareness related to the aftermaths of malaria, lower rate of treatment, together with weaker distribution channels acting as potential factors to drive the growth of malaria vaccines in African region thereby contributing to the global market. Asia Pacific is another important region, as 4% of the total confirmed cases of malaria were reported in India in 2017. This is important as 95% of India’s population live in malaria-endemic areas with around 13 million people in Bangladesh.
The global market has been bifurcated into vaccination type, agent, distribution channel and by region. Based on type of vaccine the market is further segmented into pre-erythrocytic vaccine, erythrocytic vaccine, and multi-antigen vaccine. Taking into consideration the agent used in the malaria vaccines, the international market is further divided into plasmodium falciparum, plasmodium vivax, and anopheles varieties. The distribution channels used for malaria vaccines include hospitals, clinics and community centers. Geographically, African region is expected to be the largest, however it is estimated that the Asia Pacific region would grow at a faster rate among all the other regions and Latin America likely to be the other potential regions for malaria vaccines market.
Agent Type Outlook
Vaccine Type Outlook
Distribution Channel Outlook
Know more about this report: request for sample pages
MEA, Asia Pacific and Latin America is expected to be the prominent markets for malaria vaccines globally over the forecast period of 2018-2026. It was found that around 15 million confirmed cases of malaria were reported within the Asia Pacific region in 2016. Most of the cases related to malaria in Latin America were found in the Amazon region. Based on a study published by the British Medical Journal, it was reported that Brazil in 2017, displayed an increasing rate of malaria cases. The confirmed cases of malaria in the country had grown from 14 cases per 1,000 population in 2014 to 25 cases per 1,000 population in 2015. The North America and European regions further displayed a minimal number of malaria cases in 2016.
The leading players in the market focus on latest technology and product development along with a higher focus to reach small and developing countries as a part of their business strategy. For example, according to World Health Organization (WHO), in 2015, around 292,000 children died of malaria, at the young age of 5 years in Africa. There were around 306,000 fatalities associated with malaria that was reported worldwide in 2015, out of which around 90% cases were found in Africa. As per World Health Organization (WHO), the malaria vaccines will be delivered in the regions of sub-Saharan Africa in 2018, with the funding of around US$ 15 Mn. Major players present in the global market include GlaxoSmithKline, GenVec, Inc., Nobelpharma,and Sanaria. Other promising vendors are Cadila Healthcare Ltd., VLP Therapeutics LLC, CellFree Sciences Co. Ltd., and Genome ReS Ltd. among others.